Reports Q1 revenue $195M, consensus $193.88M. “CARVYKTI, underpinned by its continued strong commercial performance, continues to set the standard for CAR-T therapies in multiple myeloma,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech (LEGN). “We believe our achievements from this past quarter, including capacity expansion and additional global approvals, are setting the stage for Legend Biotech to achieve company-wide profitability by next year. As we unlock new markets and meet growing global demand, we believe our manufacturing expansion and commercial execution will maintain CARVYKTI’s market leadership position and enable us to deliver our differentiated cell therapy to more patients around the world.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Announces Annual General Meeting for June 2025
- LEGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Legend Biotech Stock (LEGN) Up on Strong Sales and Bullish Analyst Outlook
- Strong Growth and Market Potential Drive Buy Rating for Legend Biotech’s CARVYKTI
- Legend Biotech: Strong Buy Rating Backed by Impressive CARVYKTI Sales and Strategic Expansion Plans
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue